Hepatitis C Virus Retreatment Successful with SOF/VEL/VOX in Patients With and Without HIVNovember 13th 2018
A fixed-dose combination therapy (Vosevi, Gilead) was highly effective after 12 weeks in retreating direct-acting antiviral-experienced patients with hepatitis C virus infection, with and without HIV co-infection, including those with prior noncompletion of treatment or poor adherence.
OPAT-Antimicrobial Stewardship Team Coordination Ideal For Improving Patient Outcomes Upon ReadmissionOctober 7th 2018
Efforts such as improved indication documentation and antimicrobial stewardship involvement may improve patient outcomes in some patients who are on outpatient parenteral antimicrobial therapy (OPAT) for ease of administration (EOA) that are readmitted to the hospital.
Recommended Gonorrhea Treatment Regimen Not Received by 20% of Patients in the USMay 30th 2018
Although most health care providers are adhering to the recommended regimen, the US Centers for Disease Control and Prevention reports that about 20% of patients with uncomplicated gonorrhea are not receiving the recommended dual regimen designed to ward off resistance.
Patient Demand Outweighs Guidelines When it Comes to Appropriate Prescribing of AntibioticsApril 21st 2018
According to recent research from Johns Hopkins Medicine, when it comes to making choices on appropriate antibiotic prescribing, outpatient providers are making the decision based on patient demand, not necessarily on what's actually appropriate for the condition.
Yellow Fever Vaccine Needed Before Traveling to Brazil, CDC Warns “Don't Chance It”March 17th 2018
In the wake of news of 10 travelers being infected with yellow fever, 4 of whom have died, the Centers for Disease Control and Prevention (CDC) are urging anyone considering travel to yellow fever endemic regions of Brazil to be vaccinated prior to travel.
New Single-Tablet HIV Treatment Regimen Performs Well in Treatment-Experienced Patients Across All Race, Gender, and Age GroupsMarch 16th 2018
Posthoc analysis of the EMERALD trial reveal the combination regimen of D/C/F/TAF performs well in HIV-positive patients across different race, gender, and age subgroups, who may have failed previous antiviral regimens.